pages:
-
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of ETC-1922159 In Advanced Solid Tumours
-
A Phase 1b MAD Study of TT301/MW189
-
A Phase 1b Multicenter, Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of PF-06939926 in Ambulatory Subjects with Duchenne Muscular Dystrophy" Protocol # C3391001 (hereinafter the "Study")
-
A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus
-
A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleucel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma
-
A phase 1b Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF).
-
A Phase 1b, 12-Week, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of PF-06946860 In Patients with Non-Small Cell Lung Cancer and Cachexia
-
A Phase 1b, Multicenter, double blind randomized controlled dose escalating trial
of fentanyl vs. fentanyl + dexmedetomidine as the initial regimen for maintenance
of sedation in mechanically-ventilated, critically ill children
-
A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis
-
A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic Pemphigus (Vulgaris or Foliaceus)
-
A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer
-
A Phase 1b, Open-label Single dose study to Evaluate the Pharmacokinetics, Safety and Tolerability of MK-7655A in Pediatric Subjects from Birth to less than 18 years of Age with Confirmed or Suspected Gramnegative Infections
-
A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn
-
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors
-
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination with Conatumumab in Subjects with Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
-
A Phase 1b, Open-Label, Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients with Presumed Nonalcoholic Steatohepatitis (NASH)
-
A Phase 1b, Prospective, Multicenter, Randomized, Single Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema (DME)
Research Grant
-
A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability of Intervention with AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
-
A phase 1b, randomized, double-blind, placebo-controlled, multiple-ascending dose study to investigate the safety, tolerability and pharmacokinetics of DSTA4637A in patients with Staphylococcus Aureus Bacteremia receiving standard-of-care antibiotics
-
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T
-
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Ge
-
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor Administered with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours
-
A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma""
-
A Phase 1b/2 open label dose escalation study of Margetuximab incombination with Pembrolizumab in patients with relapsed refrectory advanced HER2 + Gastroesophageal junction or gastric cancer.
-
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
-
A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma
-
A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
-
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
-
A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center
-
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in
Participants with RCC (U03):
pages: